Multi-modal 3D visualization of neuroblastoma (Multi3DVis – NBL)
Preoperative imaging in neuroblastoma: what is the value of the MIBG scan and MRI in surgical planning?
Recruiting
Who can enter
Children with neuroblastoma who are undergoing surgery to remove the tumor
Age: 0 to 18 years
Goal
Goal
In this study, we aim to compare tumor tissue that has been removed during surgery with the MRI and MIBG scans taken before the operation. With this comparison, we hope to investigate the tumor in greater detail.
Background
Background
During surgery for neuroblastoma, as much tumor tissue as possible is removed. This can be challenging because neuroblastoma often grows around and into major blood vessels and vital organs.
Sometimes, the surgeon has to decide to leave some tissue behind. In making such decisions, the preoperative MRI and/or MIBG scans are reviewed. If these scans show that the piece of tissue in question still absorbs MIBG or appears very active on the MRI, the surgeon may be willing to take more risk to remove it than if the scans suggest it is no longer active tumor tissue. However, we are not certain how well these scans correlate with tissue examination results.
Therefore, in this study, we want to link the imaging results — the MRI and MIBG scans — to the tissue examination results after surgery. This will help us investigate whether we can identify active tissue before surgery that needs to be removed, and also recognize inactive tissue that might safely be left behind if it cannot be removed without risk.
No additional procedures or measurements are required for this study, and it poses no risks to the patient. The data used are part of standard clinical care.
In order to participate in a study please refer to your/your child’s doctor.
Last reviewed
Last reviewed
September 22, 2025
Study details
- Study details
Official title
Multi-modal 3D visualization of pediatric neuroblastoma: aiding surgical planning beyond anatomical information.Cancer type
NeuroblastomaMaximum number of patients
60, all in the NetherlandsStart date
September 22, 2025Status
OpenLocal principal investigator
Dr. Lideke van der SteegSponsor
Princess Maxima Center for pediatric oncologyApproval
This study has been reviewed and approved by the internal scientific committee (Clinical Research Committee) of the Princess Máxima Center. An accredited medical research ethics committee waived the need for official approval according to the Medical Research Involving Human Subjects Act (WMO), and is therefore not further involved in the review of the research. This is only done for studies with low risk or low patient burden. More information: CCMO.
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.